S100B and myeloid sarcoma: In MS patients, increased levels of S100B in CSF and serum have been reported, and this increase may cause activation of microglia and astrocytes, as well as oligodendrocyte demise, exacerbating tissue damage during an MS episode or delaying re-myelination [5, 15].